WO2016183173A1 - Composés antiparasitaires - Google Patents

Composés antiparasitaires Download PDF

Info

Publication number
WO2016183173A1
WO2016183173A1 PCT/US2016/031814 US2016031814W WO2016183173A1 WO 2016183173 A1 WO2016183173 A1 WO 2016183173A1 US 2016031814 W US2016031814 W US 2016031814W WO 2016183173 A1 WO2016183173 A1 WO 2016183173A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridyl
thiazol
compound
trifluoromethyl
benzamide
Prior art date
Application number
PCT/US2016/031814
Other languages
English (en)
Inventor
Jason Daniel Speake
Brent Christopher Beck
Weiming Fan
Original Assignee
Avista Pharma Solutions
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avista Pharma Solutions filed Critical Avista Pharma Solutions
Publication of WO2016183173A1 publication Critical patent/WO2016183173A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • thiazole derivatives Disclosed herein are thiazole derivatives, compositions comprising them, processes for their preparation, intermediates useful in their synthesis, and their use as antiparasitic agents.
  • the compounds of the invention are useful in the treatment or prevention of parasitic helminth infection.
  • Parasitic helminths can cause many diseases and conditions of medical, veterinary, and agricultural importance. They can infect humans and other mammals, particularly companion animals such as dogs and cats as well as animals of agricultural importance such as sheep, cattle, horses, goats, fish, pigs, and poultry, causing many pathological effects and symptoms.
  • EP 455356 describes the preparation of 5-amino-l,2,4-thiadiazoles useful as immunosuppressants.
  • International Patent Publication No. WO 2006/033005 discloses the preparation of oxazolyl, thiazolyl or thiadiazolyl pyrimidinylamino benzamide derivatives as thrombopoietin receptor agonists.
  • WO2007/037543 discloses the preparation of biarylamide derivatives as inhibitors of metabotropic glutamate receptor 1 (mGluRl).
  • WO2002/100826 discloses the preparation of 3,5- diaryl-l,2,4-oxadiazoles and analogs useful as activators of caspases and inducers of apoptosis.
  • WO1993/19054 discloses certain N-heterocyclic nitro anilines as fungicides, and refers to the use of these compounds to treat nematodes.
  • WO2007/087427 discloses preparation of thiazole and thiadiazole compounds for treating inflammation, immune disorders, and other diseases.
  • WO2005/063743 discloses synthesis of thiazole derivatives for adenosine A2A receptor antagonist.
  • WO2001/007423 discloses preparation of heterocycles in drug compositions exhibiting thrombopoietin agonism.
  • WO 2003/062233 discloses preparation of 2-acylaminothiazole derivatives or salts thereof as c-Mpl receptor ligands.
  • WO 2002/062775 discloses preparation of 2-acylaminothiazole derivatives or their salts as promoters of megakaryocyte colony formation.
  • X is R 1 or NHR 1 ;
  • R 1 - phenyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, -NR 3 R 4 ,
  • naphthyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 ,
  • -CO HC 6 H5 hydroxy, alkoxy, aryloxy, aryl, heterocyclyl, haloalkyl, haloalkoxy, mercapto (-SH), thioalkyl and halogen;
  • quinoxolinyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 , cyano, - R 3 COR 5 , alkyl, -S0 2 R 5 , - R 3 S0 2 R 5 , -S0 2 R 3 R 4 , -CO R 3 R 4 ,
  • -CO HC 6 H 5 hydroxy, alkoxy, aryloxy, aryl, heterocyclyl, haloalkyl, haloalkoxy, mercapto (-SH), thioalkyl and halogen;
  • quinolyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 ,
  • -CO HC 6 H5 hydroxy, alkoxy, aryloxy, aryl, heterocyclyl, haloalkyl, haloalkoxy, mercapto (-SH), thioalkyl and halogen;
  • thionyl or furyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 , cyano, - R 3 COR 5 , alkyl, -S0 2 R 5 , - R 3 S0 2 R 5 , -S0 2 R 3 R 4 , -CO R 3 R 4 , -CO HC 6 H 5 , hydroxy, alkoxy, aryloxy, aryl, heterocyclyl, haloalkyl, haloalkoxy, mercapto (-SH), thioalkyl and halogen;
  • R 2 is hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, aminoalkyl,
  • alkylaminoalkyl aryl, heterocyclyl or -CO R 3 R 4 ; or
  • R 2 together with two adjacent carbon atoms of the pyridyl ring to which it is attached, forms a saturated or unsaturated ring containing from 4 to 6 ring atoms;
  • R 3 and R 4 which are the same or different, each represent hydrogen or alkyl; or when R 3 and R 4 are each attached to a nitrogen atom, they may form a saturated or unsaturated heterocyclic ring containing from 4 to 6 ring atoms;
  • R 5 is alkyl, haloalkyl
  • Z is halo, haloalkyl, cyano, optionally substituted alkyl, alkoxy, -CO R 3 R 4 , optionally substituted cycloalkyl, aminoalkyl, alkylaminoalkyl, optionally substituted heterocyclyl, or optionally substituted aryl;
  • substituents R 1 , R 2 , R 3 , R 4 and R 5 can contribute to optical and/or stereoisomerism. All such forms are encompassed by exemplary embodiments described herein.
  • compositions comprising a compound of formula (I) along with a pesticidally acceptable excipient, carrier or diluent.
  • the compositions of the invention can also be in a variety of forms which include, but are not limited to, oral formulations, injectable formulations, and topical, dermal or subdermal formulations.
  • the formulations are intended to be administered to an animal which includes but is not limited to mammals, birds and fish. Examples of mammals include but are not limited to humans, cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys, dogs, cats and other livestock or domestic mammals.
  • birds examples include turkeys, chickens, ostriches and other livestock or domestic birds.
  • compositions comprising a compound of formula (I) suitable for treatment of a locus that may be infected with parasites, such as a plant or animal, or for the prevention of infection of a locus with parasites.
  • a combination therapy whereby the compounds of formula (I) can be employed as such or in the form of their preparations (formulations) as combinations with other pesticidally active substances, such as, for example, insecticides, attractants, sterilants, nematicides, acaricides, fungicides, herbicides, and with safeners, fertilizers and/or growth regulators.
  • pesticidally active substances such as, for example, insecticides, attractants, sterilants, nematicides, acaricides, fungicides, herbicides, and with safeners, fertilizers and/or growth regulators.
  • the combinations may be part of the same formulation, or may be administered separately or sequentially to the locus.
  • a compound of formula (I), or a composition comprising a compound of formula (I), for use in treating or preventing parasitic infection is provided herein.
  • a compound of formula (I) for the manufacture of a medicament for use in treating or preventing parasitic infection.
  • a method of treating or preventing a parasitic infection comprising the administration of an effective amount of a compound of formula (I), or a composition comprising a compound of formula (I) to a locus.
  • Alkoxy where described in a substituent (e.g. 'alkoxy', 'haloalkoxy') refers to the group -OR where R is alkyl. This term is illustrated by the groups methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy and
  • Alkyl where described in a substituent (e.g. 'alkyl', 'haloalkyl', 'thioalkyl') refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 20 carbon atoms, preferably 1-8 carbon atoms, preferably up to 6 (e.g. 1-6) carbon atoms.
  • the hydrocarbon chain can be either straight-chained or branched. This term is illustrated by the groups methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, and tert-butyl, cyclohexyl, cyclobutyl, cyclopentyl .
  • Halogen or "halo" where described in a substituent refers to a halogen, preferably Br, CI or F.
  • Heterocyclyl refers to a saturated or unsaturated ring containing from 4 to 6 ring atoms and from 1 to 4 heteroatoms which may be the same or different selected from nitrogen, oxygen and sulphur, such as pyridyl, morpholino, piperidinyl, piperizinyl, pyrazolyl, tetrazolyl, oxazolyl, thiazolyl, pyranyl, furanyl, oxetanyl, azetidinyl, pyrrolidinyl.
  • Aryl where described in a substituent (e.g. 'aryl', 'aryloxy') refers to a substituted or unsubstituted aromatic ring system of from 5 to 10 atoms, such as phenyl, naphthyl, 4-trifluoromethylphenyl.
  • a “saturated or unsaturated ring containing from 4 to 6 ring atoms” refers to a ring containing only carbon atoms, or a heterocyclic ring containing carbon atoms and non-carbon atoms (e.g. N).
  • “Pesticidally acceptable salt” refers to any salt of a compound disclosed herein which retains its biological properties and which is not toxic or otherwise undesirable for pesticidal use. Such salts may be derived from a variety of organic and inorganic counter-ions well known in the art.
  • Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, gly colic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4- hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric,
  • organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylprop
  • Salts further include, by way of example only salts of non-toxic organic or inorganic acids, such as halides, e.g., chloride and bromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate,
  • halides e.g., chloride and bromide
  • sulfate phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate
  • cyclopentylpropionate glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4- hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane-di sulfonate, 2- hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2- naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4- methylbicyclo[2.2.2]-oct-2-ene-l-carboxylate, glucoheptonate, 3-phenylpropionate,
  • enantiomers Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers".
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is designated (R) or (S) according to the rules of Cahn and Prelog (Cahn et al, 1966, Angew. Chem. 78: 413-447, Angew. Chem., Int. Ed. Engl. 5: 385-414 (errata: Angew. Chem., Int. Ed. Engl. 5:511); Prelog and Helmchen, 1982, Angew. Chem. 94: 614- 631, Angew. Chem. Internal Ed. Eng. 21 : 567-583; Mata and Lobo, 1993,
  • Tetrahedron Asymmetry 4: 657-668 or can be characterized by the manner in which the molecule rotates the plane of polarized light and is designated dextrorotatory or levorotatory ⁇ i.e., as (+)- or (-)-isomers, respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture".
  • the compounds disclosed herein can possess one or more asymmetric centers; such compounds can therefore be produced as the individual (R)- or ( ⁇ -enantiomer or as a mixture thereof.
  • the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof.
  • Methods for determination of stereochemistry and separation of stereoisomers are well-known in the art.
  • stereoisomers of the compounds provided herein are depicted upon treatment with base.
  • the compounds disclosed herein are "stereochemically pure".
  • a stereochemically pure compound has a level of stereochemical purity that would be recognized as “pure” by those of skill in the art. Of course, this level of purity will be less than about 100%.
  • "stereochemically pure” designates a compound that is substantially free, i.e. at least about 85% or more, of alternate isomers.
  • the compound is at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or about 99.9% free of other isomers.
  • the terms “subject” and “patient” are used interchangeably herein.
  • the terms “subject” and “subjects” refer to a primate (e.g., a monkey such as a cynomolgous monkey, a chimpanzee and a human) or non-primate animal.
  • the subject is a human.
  • the subject is a companion animal such as a dog or cat.
  • the subject is an animal of agricultural importance such as a sheep, cow, horse, goat, fish, pig, or domestic fowl (such as a chicken, turkey, duck or goose).
  • X is R 1 or HR 1 ;
  • R 1 is:
  • phenyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, -NR 3 R 4 ,
  • naphthyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 ,
  • quinoxolinyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 , cyano, - R 3 COR 5 ,
  • alkyl -S0 2 R 5 , - R 3 S0 2 R 5 , -S0 2 R 3 R 4 , -CO R 3 R 4 , -CO HC 6 H 5 , hydroxy, alkoxy, haloalkyl, haloalkoxy, mercapto (-SH), thioalkyl and halogen; quinolyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, - R 3 R 4 ,
  • alkyl -S0 2 R 5 ,- R 3 S0 2 R 5 , -S0 2 R 3 R 4 , -CO R 3 R 4 , -CO HC 6 H 5 , hydroxy, alkoxy, haloalkyl, haloalkoxy, mercapto (-SH), thioalkyl and halogen;
  • R 2 is hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; or R 2 , together with two adjacent carbon atoms of the pyridyl ring to which it is attached, forms a saturated or unsaturated ring containing from 4 to 6 ring atoms;
  • R 3 and R 4 which are the same or different, each represent hydrogen or alkyl
  • R 5 is alkyl
  • Z is haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl.
  • X is - HR 1 . In a further embodiment, X is R 1 .
  • R 1 is phenyl optionally substituted by from one to three substituents which are the same or different selected from the group consisting of trifluoromethyl, trifluoromethoxy, halogen, methyl, ethyl, methoxy, ethoxy, thiomethyl, -S0 2 CH 3 , -S0 2 H 2 , -S0 2 HCH 3 , -S0 2 N(CH 3 ) 2 and - HS0 2 CH 3 , with the proviso that when Z is 3 -trifluoromethylphenyl, the optional substitution is not 2,5-difluoro.
  • R 1 is phenyl substituted by from 1 to 3 substituents which are the same or different selected from the group consisting of halogen, cyano, haloalkyl, alkoxy and haloalkoxy, with the proviso that when Z is 3- trifluoromethylphenyl, the optional substitution is not 2,5-difluoro or with the proviso that when Z is 1-piperidinyl, the optional substitution is not 3,5-dimethoxy; or R 1 is naphthyl optionally substituted by from 1 to 3 substituents which are the same or different selected from the group consisting of halogen, cyano, haloalkyl, alkoxy and haloalkoxy.
  • R 2 is hydrogen or halogen. In yet a further embodiment R 2 is hydrogen.
  • Z is haloalkyl or optionally substituted heterocyclyl. In yet a further embodiment Z is haloalkyl. In yet a further embodiment Z is optionally substituted heterocyclyl.
  • A, X, Z, R 1 and R 2 can be independently selected with respect to the A, X, Z, R 1 , R 2 , R 3 , R 4 and R 5 substituents, respectively.
  • X is HR 1 ;
  • R 1 is phenyl optionally substituted by from one to three substituents which are the same or different selected from the group consisting of trifluoromethyl, trifluoromethoxy, halogen (e.g. chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy, thiomethyl, -S0 2 CH 3 , -S0 2 H 2 , -S0 2 HCH 3 , -S0 2 N(CH 3 ) 2
  • substituents which are the same or different selected from the group consisting of trifluoromethyl, trifluoromethoxy, halogen (e.g. chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy, thiomethyl, -S0 2 CH 3 , -S0 2 H 2 , -S0 2 HCH 3 , -S0 2 N(CH 3 ) 2
  • R 2 is hydrogen, fluoro, methyl, trifluoromethyl, methoxy or
  • X is R 1 ;
  • R 1 is phenyl substituted by from one to three substituents which are the same or different selected from the group consisting of trifluoromethyl,
  • R 2 is hydrogen, fluoro, methyl, trifluoromethyl, methoxy
  • Z is haloalkyl, cyano, optionally substituted alkyl, alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted aryl;
  • A is S0 2 ;
  • X is R 1 ;
  • R 1 is phenyl substituted by from one to three substituents which are the same or different selected from the group consisting of trifluoromethyl,
  • R 2 is hydrogen.
  • X is R 1 or HR 1 ;
  • R 1 is:
  • phenyl optionally substituted by from one to three substituents which are the same or different, each selected from the group consisting of nitro, -NR 3 R 4 ,
  • R 2 is hydrogen, fluoro, methyl, trifluoromethyl, methoxy, trifluoromethoxy, morpholino, aminoalkyl or dimethylaminomethyl.
  • Z is haloalkyl, cyano, optionally substituted alkyl, alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted aryl;
  • the compounds are selected from the following compounds ("Cpd" means Compound) of Table 1 :
  • R 1 and A are as defined above and X 1 is a leaving group.
  • the reaction is generally carried out in an aprotic solvent (e.g. tetrahydrofuran) at a temperature from about 0 to about 100°C.
  • aprotic solvent e.g. tetrahydrofuran
  • X 1 is a halogen, such as chlorine.
  • the reaction is generally carried out in an aprotic solvent (e.g. tetrahydrofuran) at a temperature from about 0 to about 100°C.
  • compounds of formula (I) in which A is S0 2 and X is NHR 1 can be prepared by the reaction of a compound of formula (I) with a compound of formula X ⁇ OzNHR 1 , wherein X 1 and R 1 are as defined above.
  • compositions including at least one compound of the present invention, if appropriate in the salt form, either used alone or in the form of a combination with one or more compatible and pesticidally acceptable carriers, such as diluents or adjuvants, or with another agent.
  • compositions which comprise a thiazole derivative of formula (I) or a salt thereof, and an acceptable excipient, carrier or diluent.
  • the composition can also be in a variety of forms which include, but are not limited to, oral formulations, injectable formulations, and topical, dermal or subdermal formulations.
  • compositions intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, bittering agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets can contain the active ingredient in admixture with non-toxic,
  • excipients which are suitable for the manufacture of tablets.
  • excipients can be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate;
  • granulating and disintegrating agents for example, corn starch, or alginic acid
  • binding agents for example, starch, gelatin or acacia
  • lubricating agents for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • Formulations for oral use can be hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin.
  • Capsules can also be soft gelatin capsules, wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.
  • the compositions can also be in the form of oil-in-water or water-in-oil emulsions.
  • the oily phase can be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
  • the emulsions can also contain sweetening agents, bittering agents, flavoring agents, and/or preservatives.
  • the composition is in the form of a
  • Microemulsions are well suited as the liquid carrier vehicle.
  • Microemulsions are quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids.
  • Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase.
  • the size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions).
  • the interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously.
  • the oily phase can be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such compounds.
  • the oily phase comprises of triglycerides; in another embodiment of the oily phase, the triglycerides are medium-chain triglycerides, for example, C 8 -Ci 0 caprylic/capric triglyceride.
  • the oily phase will represent a % v/v range selected from the group consisting of about 2 to about 15%; about 7 to about 10%; and about 8 to about 9% v/v of the microemulsion.
  • the aqueous phase includes, for example, water or glycol derivatives, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol.
  • glycol derivatives such as propylene glycol, glycol ethers, polyethylene glycols or glycerol.
  • the glycol is selected from the group consisting of propylene glycol, diethylene glycol monoethyl ether, dipropylene glycol monoethyl ether and mixtures thereof.
  • the aqueous phase will represent a proportion from about 1 to about 4% v/v in the microemulsion.
  • Surfactants for the microemulsion include diethylene glycol monoethyl ether, dipropylene glycol monomethyl ether, polyglycolyzed C 8 -Ci 0 glycerides or polyglyceryl-6 dioleate.
  • the cosurfactants include short-chain alcohols, such as ethanol and propanol.
  • the cosurfactant to surfactant ratio will be from about 1/7 to about 1/2. In another embodiment for the amount of cosurfactant, there will be from about 25 to about 75% v/v of surfactant and from about 10 to about 55% v/v of cosurfactant in the microemulsion.
  • Oily suspensions can be formulated by suspending the active ingredient in a vegetable oil, for example, atachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions can contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as sucrose, saccharin or aspartame, bittering agents, and flavoring agents can be added to provide a palatable oral preparation.
  • These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid, or other known preservatives.
  • Aqueous suspensions can contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occuring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide, with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene
  • the aqueous suspensions can also contain one or more preservatives, for example, ethyl, or n-propyl, p- hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents and/or bittering agents, such as those set forth above.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, bittering, flavoring and coloring agents, can also be present.
  • Syrups and elixirs can be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring agent(s) and/or coloring agent(s).
  • sweetening agents for example, glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, flavoring agent(s) and/or coloring agent(s).
  • compositions can be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol.
  • acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • Cosolvents such as ethanol, propylene glycol or polyethylene glycols can also be used.
  • Preservatives, such as phenol or benzyl alcohol, can be used.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Topical, dermal and subdermal formulations can include emulsions, creams, ointments, gels or pastes.
  • Organic solvents that can be used in the invention include but are not limited to: acetyltributyl citrate, fatty acid esters such as the dimethyl ester, diisobutyl adipate, acetone, acetonitrile, benzyl alcohol, butyl diglycol, dimethylacetamide,
  • 2-pyrrolidone e.g. N-methylpyrrolidone
  • diethylene glycol monoethyl ether ethylene glycol and diethyl phthalate, or a mixture of at least two of these solvents.
  • plant oils such as, but not limited to soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil, etc.
  • mineral oils such as, but not limited to, petrolatum, paraffin, silicone, etc.
  • Dosage forms can contain from about 0.5 mg to about 5 g of an active agent.
  • the active agent is present in the formulation at a concentration of about 0.05 to 10% weight/volume.
  • the compounds of the present invention can be employed as such or in the form of their preparations (formulations) as combinations with other pesticidally active substances, such as, for example, insecticides, attractants, sterilants, nematicides, acaricides, fungicides, herbicides, and with safeners, fertilizers and/or growth regulators.
  • pesticidally active substances such as, for example, insecticides, attractants, sterilants, nematicides, acaricides, fungicides, herbicides, and with safeners, fertilizers and/or growth regulators.
  • the compounds according to the invention may be combined with one or more agents having the same sphere of activity e.g. to increase activity, or with substances having another sphere of activity e.g. to broaden the range of activity. It can also be sensible to add so-called repellents.
  • repellents By combining the compounds of the present invention with other suitable parasiticides not only the parasiticidal activity can be enhanced but the greatest part of those parasites that produce great economic damage will be covered. Moreover, this action will contribute substantially to avoiding the formation of resistance.
  • Preferred groups of combination partners and especially preferred combination partners are named in the following, whereby combinations may contain one or more of these partners in addition to a compound of the present invention. Suitable partners may also be afoxolaner, sarolaner, or fluralaner or a combination thereof. Any of the individually listed agents can be used in combination with compounds of the present invention along with any other one or more listed agents independently.
  • Suitable partners in the mixture may be biocides, e.g. the insecticides and acaricides with a varying mechanism of activity, which are named in the following and have been known to the person skilled in the art for a long time, e.g. chitin synthesis inhibitors, growth regulators; active ingredients which act as juvenile hormones; active ingredients which act as adulticides; broadband insecticides, broad-band acancides and nematicides; and also the well known anthelminthics and insect- and/or acarid-deterring substances, said repellents or detachers.
  • suitable insecticides and acaricides are shown in the following table:
  • Beta-cyfluthrin 125 Flonicamid 220. Pyrachlofos
  • Beta-cypermethrin 126 Fluacrypyrim 221. Pyrafluprole 32. Bifenazate 127. Fluazinam 222. Pyresmethrin
  • Chromafenozide 154 insect-active nematodes 249. Sulprofos
  • Cis-Resmethrin 155 insect-active viruses 250. Tau-fluvalinate 61. Clofentezin 156. lprobenfos 251. Tebufenozide
  • Non-limitative examples of suitable anthelmintics are named in the following, a few representatives have anthelmintic activity in addition to the insecticidal and acaricidal activity.
  • the pharmaceutical preparation comprising the thiazole derivatives, for delivery to a human or other mammal is preferably in unit dosage form, in which the preparation is subdivided into unit doses containing an appropriate quantity of the active component.
  • the unit dosage form can be a packaged preparation containing discrete quantities of the preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet or lozenge itself, or it can be an appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation can be varied or adjusted from about 0.1 mg to about 1000 mg, according to the particular application and the potency of the active component.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • the compounds utilized in the method of treatment are administered at an initial dosage of about 0.1 mg/kg to about 100 mg/kg per interval.
  • Preferred intervals may be daily, weekly, monthly, quarterly, semi-annually, or annually.
  • the dosages can be varied depending on the requirements of the patient, for example, the size of the human or mammal being treated, the severity of the condition being treated, the route of administration, and the potency of the compound being used. Determination of the proper dosage and route of administration for a particular situation is within the skill of the practitioner.
  • the treatment will be initiated with smaller dosages which are less than the optimum dose of the compound, which can be increased in small increments until the optimum effect under the particular circumstances of the infection is reached.
  • the total daily dosage can be divided and administered in portions during the day if desired.
  • a method of treating or preventing parasite infection in a subject comprising administering to the subject an effective amount of thiazole derivative of the present invention or a pesticidally acceptable salt thereof.
  • a thiazole derivative of the present invention or a pesticidally acceptable salt thereof for treating or preventing parasite infection in a subject.
  • the compounds of the present invention are useful for the treatment or prophylaxis of parasitic helminth infections caused by nematodes, trematodes or cestodes, particularly in humans, companion animals, and veterinary animals, particularly dogs, cats, and agricultural livestock including cattle, sheep, goats, fish, pigs, equine and poultry.
  • diseases include ascariasis, filariasis, loaiasis, onchocerciasis, schistosomiasis, trichinelliasis and hydatid disease.
  • the compounds of the invention are especially useful for the prophylaxis and/or treatment of lymphatic filariasis, subcutaneous filariasis, serous cavity filariasis, onchocerciasis (river blindness), elephantiasis, heartworm (dogs and cats), Verminous haemorrhagic dermatitis (cattle) and ' Summer bleeding' (horses).
  • Examples of parasitic nematodes include, but are not limited to, Ostertagia Iyrata, O. ostertagi, O. circumcincta, Cooperia oncophora, C. pectinata, C. punctata, C.
  • Oesophagostomum radiatum, O. dentatum,.0. venulosum, O. columbianum,
  • plant-damaging nematodes include, but are not limited to, the following genera: Meloidogyne, Heterodera, Ditylenchus, Aphelenchoides, Radopholus, Globodera, Pratylenchus, Longidorus and Xiphenema.
  • parasitic cestodes include, but are not limited to: Diphyllobothrium latum, D. caninum, Echinococcus granulosus, E. multilocularis, Hymenolepsis diminuta, Taenia multiceps, T. saginatus, T. serialis, T. sohum and Vampirolepis nana.
  • parasitic trematodes examples include, but are not limited to Clonorchis sinensis, Dicrocoelium dendriticum, an echinostome, Fasciolopsis buski, Fasciola hepatica, a heterophyid, Nanophyetus salmincola, Opisthorchis felineus, O. viverrini,
  • Method A Waters BEH CI 8, 3.0 x 30 mm, 1.7 ⁇ , was used at a temperature of 50 °C and at a flow rate of 1.5 mL/min, 2 ⁇ ⁇ injection, mobile phase: (A) water with 0.1% formic acid and 1% acetonitrile, mobile phase (B) MeOH with 0.1% formic acid; retention time given in minutes.
  • Method B An Agilent Zorbax Bonus RP, 2.1 x 50 mm, 3.5 ⁇ , was used at a temperature of 50 °C and at a flow rate of 0.8 mL/min, 2 injection, mobile phase: (A) water with 0.1% formic acid and 1% acetonitrile, mobile phase (B) MeOH with 0.1%) formic acid; retention time given in minutes.
  • Method C An API 150EX mass spectrometer linked to a Shimadzu LC-10AT LC system with a diode array detector was used.
  • the spectrometer had an electrospray source operating in positive and negative ion mode.
  • LC was carried out using an Agilent ZORBAX XDB 50 x 2.1 mm C18 column and a 0.5 mL/minute flow rate.
  • Solvent A 95% water, 5% acetonitrile containing 0.01% formic acid;
  • Solvent B acetonitrile. The gradient was shown as below.
  • the compounds of the present invention were tested for activity against Dirofilaria immitis.
  • Dirofilaria immitis microfilariae are isolated by filtration from blood of an infected beagle dog allowed to incubate at 37C/5%C0 2 /95%RH in RPMI media.
  • For assay 500 microfilariae are added into 96-well plates followed by addition of compounds diluted in DMSO for single-point or dose response (5-point) analysis.
  • Ivermectin or emodepside are included as a positive control and DMSO-only wells are included as negative controls. Plates containing parasites and compounds are incubated at 37°C/5%C0 2 /95%RH for 72 hours and motility is assessed using an LCD camera imaging system. Percent motility inhibition values are generated relative to the average of the DMSO-only wells.
  • For dose response analysis data points were averaged and curve fitting software is used to generate sigmoidal curves for the determination of EC 50 values (i.e. the effective concentration to kill 50% of the organism).
  • D. immitis L3 larvae of D. immitis are isolated from infected mosquitoes and allowed to moult into L4 stages in culture. Approximately 5-10 D. immitis L4 stage parasites are added to 96-well plates containing RPMI media and incubated at 37C/5%C0 2 /95%RH.
  • the compounds of the invention are diluted in dimethyl sulfoxide (DMSO) and added at a single dose to identify those that affect parasite motility upon microscopic inspection or automated imaging after 72 hours of incubation. Compounds with activity at that concentration are progressed to a five-point dose titration assay and evaluated by microscopic examination or automated imaging of the wells after incubation for 72 hours. Efficacy is based on reduction in motility of the treated L4 larvae as compared to the positive (ivermectin or emodepside) and negative (DMSO) controls.
  • DMSO dimethyl sulfoxide
  • L929 fibroblasts are seeded at 2,000 cells/well and exposed to 2-fold dilutions of test compounds directly parallel to the assay for parasitic activity. Plates with parasites or L929 cells are incubated with compounds under appropriate conditions for each cell type. Tamoxifen and taxol are included as a positive control and DMSO-only wells are included as negative controls. After 72 hours of incubation, resazurin (20 ⁇ _, of 12.5 mg/mL stock in phosphate buffered saline) was added to each well and plates are incubated for an additional 4-6 h.
  • the compounds of the invention demonstrated activity against D. immitis microfilariae or D. immitis L4 stage.
  • the following compounds were determined to have EC 50 values less than 5 ⁇ :

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de thiazole et leur utilisation pour le traitement de parasites.
PCT/US2016/031814 2015-05-12 2016-05-11 Composés antiparasitaires WO2016183173A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160188P 2015-05-12 2015-05-12
US62/160,188 2015-05-12

Publications (1)

Publication Number Publication Date
WO2016183173A1 true WO2016183173A1 (fr) 2016-11-17

Family

ID=57249474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/031814 WO2016183173A1 (fr) 2015-05-12 2016-05-11 Composés antiparasitaires

Country Status (1)

Country Link
WO (1) WO2016183173A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806304A (zh) * 2019-04-09 2019-05-28 大理大学 三叶悬钩子植物提取物及其药物组合物的制备方法与抗旋毛虫用途
WO2019105875A1 (fr) 2017-11-28 2019-06-06 Bayer Aktiengesellschaft Composés hétérocycliques utilisés en tant que pesticides
WO2021097057A1 (fr) * 2019-11-12 2021-05-20 Genzyme Corporation Hétéroarylaminosulfonamides à 5 chaînons pour le traitement d'états à médiation par une activité cftr déficiente
CN115850258A (zh) * 2022-12-27 2023-03-28 东北林业大学 一种马赛替尼的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087427A2 (fr) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Composes thiazole et thiadiazole destines a des utilisations associees a une inflammation et au système immunitaire
US20140249024A1 (en) * 2011-07-15 2014-09-04 Basf Se Pesticidal Methods Using Substituted 3-pyridyl Thiazole Compounds and Derivatives for Combating Animal Pests II
US20150111731A1 (en) * 2013-10-22 2015-04-23 Dow Agrosciences Llc Pesticidal compositions and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087427A2 (fr) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Composes thiazole et thiadiazole destines a des utilisations associees a une inflammation et au système immunitaire
US20140249024A1 (en) * 2011-07-15 2014-09-04 Basf Se Pesticidal Methods Using Substituted 3-pyridyl Thiazole Compounds and Derivatives for Combating Animal Pests II
US20150111731A1 (en) * 2013-10-22 2015-04-23 Dow Agrosciences Llc Pesticidal compositions and related methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAIN, A. U. P. ET AL.: "Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites", J. MED. CHEM., vol. 57, no. 11, 2014, pages 4521 - 4531, XP055321153 *
MJAMBILI, F. ET AL.: "Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents", BIOORGANIC&MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 2, 2014, pages 560 - 564, XP055208364 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019105875A1 (fr) 2017-11-28 2019-06-06 Bayer Aktiengesellschaft Composés hétérocycliques utilisés en tant que pesticides
CN109806304A (zh) * 2019-04-09 2019-05-28 大理大学 三叶悬钩子植物提取物及其药物组合物的制备方法与抗旋毛虫用途
WO2021097057A1 (fr) * 2019-11-12 2021-05-20 Genzyme Corporation Hétéroarylaminosulfonamides à 5 chaînons pour le traitement d'états à médiation par une activité cftr déficiente
CN115003659A (zh) * 2019-11-12 2022-09-02 健赞公司 用于治疗由cftr活性缺乏介导的疾患的5元杂芳基氨基磺酰胺
CN115850258A (zh) * 2022-12-27 2023-03-28 东北林业大学 一种马赛替尼的合成方法

Similar Documents

Publication Publication Date Title
US9643963B2 (en) Antiparasitic compounds
CA2780522C (fr) Composes insecticides a base de derives isoxazoline
US10772331B2 (en) Antiparasitic compounds
WO2016183173A1 (fr) Composés antiparasitaires
US20200181134A1 (en) Antiparasitic Compounds
EP3710453A1 (fr) Composés antiparasitaires à énantiomère unique
TW201307282A (zh) 基於芳基硫乙醯胺衍生物之殺昆蟲化合物
TW201528952A (zh) 以異唑啉衍生物爲主之殺蟲化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16793428

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16793428

Country of ref document: EP

Kind code of ref document: A1